奈达铂化疗同步放疗治疗局部晚期鼻咽癌45例  

Nedaplatin Chemotherapy with Concurrent Radiotherapy in the Treatment for 45 Cases with Locally Advanced Nasopharyngeal Carcinoma

作　　者：熊锐华[1] 田秀荣[1] 任庆[1] 唐新云[1] 

机构地区：[1]中国人民解放军第181医院,广西桂林541002

出　　处：《肿瘤学杂志》2011年第6期435-437,共3页Journal of Chinese Oncology

摘　　要：[目的]探讨奈达铂化疗同步放疗治疗局部晚期鼻咽癌的疗效和不良反应。[方法]84例局部晚期鼻咽癌患者,随机分为奈达铂组(45例)和顺铂组(39例),两组在根治性放疗的同时给予奈达铂(奈达铂100mg/m2静滴d1、22、43)或顺铂(顺铂100mg/m2,静滴d1、22、43)化疗。[结果]奈达铂组CR42例(93.3%),PR3例(6.7%),顺铂组CR35例(89.7%),PR4例(10.3%),两组疗效差异无显著性(P>0.05)。奈达铂组和顺铂组胃肠道反应发生率分别为22.2%和46.2%,差异有显著性(P<0.05),两组骨髓抑制、肝、肾功能损害、皮肤黏膜反应发生率差异均无统计学意义(P>0.05)。[结论]奈达铂化疗同步放疗治疗局部晚期鼻咽癌疗效确切,不良反应可耐受。[Purpose] To investigate the response and side effect of nedaplatin （NDP） chemotherapy with concurrent radiotherapy for patients with locally advanced nasopharyngeal carcinoma. [Methods] Ninety-four cases with locally advanced nasopharyngeal carcinoma were randomized divided into the NDP group （n=45） and DDP group（n=39）.All patients received radical radiation with concurrent NDP （NDP 100mg/m^2, intravenous,d1,22,43） or DDP （DDP 100mg/m^2,intravenous,d1,22,43） chemotherapy. [Results] In NDP group, CR was 42 cases（93.3%）, PR was 3 cases（6.7%）. In DDP group, CR was 35 cases （93.3%）, PR was 4 cases （6.7%）. There was no significant difference of the response between the two groups （P〉0.05）.The gastrointestinal toxicity in NDP group and DDP group was 22.2% and 46.2%,with significant difference （P〈0.05）. The rate of myelosuppression, renal/ liver dysfunction and skin-mucosal side effects had no significantly different between the two groups （P〉0.05）. [Conclusions] NDP chemotherapy with concurrent radiotherapy for patients with locally advanced nasopharyngeal carcinoma is effective and tolerable.

关 键 词：鼻咽肿瘤 奈达铂 同步放化疗 顺铂 

分 类 号：R739.63[医药卫生—肿瘤]